Oncology

Lenvima-treated patients experienced a median of 18.3 progression-free months.

Diabetics who took metformin saw a decreased chance of developing adenocarcinoma.

Annual rate of primary tumor removal has decreased since 1988.

Cells found to hijack vitamin D receptors to repair damage caused by therapy.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

Trend reflects growing tobacco epidemic among women.

Genomic sequencing reveals effect of hepatitis on genetic mutations in tumors.

A recent study has identified how chronic hepatitis infection can pave the way to liver cancer.

Phase 3 trial for polycythemia vera drug significantly improved hematocrit control without the need for phlebotomy.

Progression-free survival improved from treatment during phase 3 trial.

Palbociclib inhibits molecules that promote cancer cell growth.

Research identifies how tumors resist current treatments.

Treatment was previously designated as a breakthrough therapy for bladder cancer.

The FDA today granted accelerated approval to a drug that treats breast cancer in postmenopausal women by attacking molecules that promote cancer cell growth.

Technology locates tumors otherwise obscured by dense breast tissue on a mammogram.

If you use erythropoiesis stimulating agents (ESAs) in your hospital or clinic, then here is a refresher of the ESA APPRISE Program.

Smokers have greater risk for recurrence of cancer.

Women diagnosed with polycystic ovary syndrome are more likely to develop heart disease, diabetes, and other chronic conditions than those without the hormone disorder.

Use of a hormonal contraceptive for at least 5 years linked to potential increase in development of glioma of the brain.

Repurposing drugs that block sodium channels may offer a novel therapy for cancer.

The FDA today approved the expanded use of a breakthrough therapy for the treatment of a rare form of cancer that attacks the immune system.

Benefits of tamoxifen varies among patients.

Cardinal Health Specialty Solutions today announced that it has signed a three-year agreement with RainTree Oncology Services to serve as its exclusive distributor for injectable, infused, oral oncolytic and supportive care specialty medications; and for Cardinal Health's VitalSourceTM to serve as its group purchasing organization for injectable and infused medications.

Vitamin D can stimulate the immune system to protect against a specific type of colorectal cancer.

Researchers discover how cancer resists BRAF+MEK inhibitors.

Eribulin evaluated for the first time as an early metastatic breast cancer treatment.

Chimeric antigen receptor may be able to treat a number of cancer types.

Pathway discovered that allows aggressive tumors to proliferate.

Protective effect less clear for cutaneous melanoma.

Exclusive interviews with keynote speaker Lunden and program chairman Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, outline cutting edge treatments for patients.